Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

COVID-19 Death and BCG Vaccination Programs Worldwide

  • Jirjees, Feras J. (College of Pharmacy, University of Sharjah) ;
  • Bashi, Yahya H. Dallal (School of Pharmacy, Queen's University Belfast) ;
  • Al-Obaidi, Hala J. (School of Pharmacy, Queen's University Belfast)
  • Received : 2020.06.18
  • Accepted : 2020.09.04
  • Published : 2021.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guérin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end of May 2020, the available information on the COVID-19 pandemic indicated the great effect of the BCG vaccine in reducing the number of COVID-19 death cases. The occurrence of death due to COVID-19 was found to be 21-fold lower in countries with a national BCG vaccination policy than in countries without such a policy, based on the medians of COVID-19 death case per 1 million of the population in these two groups of countries (p<0.001, Mann-Whitney test). Therefore, it can be concluded that the early establishment of a BCG vaccination policy in any country is a key element in reducing the number of COVID-19 and tuberculosis death cases.

Keywords

References

  1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470-3. https://doi.org/10.1016/S0140-6736(20)30185-9
  2. World Health Organization. Coronavirus disease (COVID-19): situation report - 130 [Internet]. Geneva: World Health Organization; 2020 [cited 2020 May 29]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200529-covid-19-sitrep-130.pdf?sfvrsn=bf7e7f0c_4.
  3. Hegarty PK, Kamat A, Zafirakis H, DiNardo A. BCG vaccination may be protective against Covid-19. Preprint at https://doi.org/10.13140/RG.2.2.35948.10880 (2020).
  4. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced mortality for COVID-19. Preprint medRxiv at https://doi.org/10.1101/2020.03.24.20042937 (2020).
  5. British Lung Foundation. Tuberculosis. London: British Lung Foundation; 2020 [cited 2020 Apr 25]. Available from: https://www.blf.org.uk/support-for-you/tuberculosis.
  6. Luca S, Mihaescu T. History of BCG vaccine. Maedica (Bucur) 2013;8:53-8.
  7. Covian C, Fernandez-Fierro A, Retamal-Diaz A, Diaz FE, Vasquez AE, Lay MK, et al. BCG-induced cross-protection and development of trained immunity: implication for vaccine design. Front Immunol 2019;10:2806. https://doi.org/10.3389/fimmu.2019.02806
  8. Tanner R, Villarreal-Ramos B, Vordermeier HM, McShane H. The humoral immune response to BCG vaccination. Front Immunol 2019;10:1317. https://doi.org/10.3389/fimmu.2019.01317
  9. Bosteels C, Neyt K, Vanheerswynghels M, van Helden MJ, Sichien D, Debeuf N, et al. Inflammatory type 2 cDCs acquire features of cDC1s and macrophages to orchestrate immunity to respiratory virus infection. Immunity 2020;52:1039-56. https://doi.org/10.1016/j.immuni.2020.04.005
  10. de Castro MJ, Pardo-Seco J, Martinon-Torres F. Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clin Infect Dis 2015;60:1611-9. https://doi.org/10.1093/cid/civ144
  11. Global tuberculosis report 2019 (WHO/CDS/TB/2019.15) [Internet]. Geneva: World Health Organization; 2019 [cited 2020 May 1]. Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1.
  12. Mangtani P, Nguipdop-Djomo P, Keogh RH, Trinder L, Smith PG, Fine PE, et al. Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guerin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. Health Technol Assess 2017;21:1-54.
  13. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994;271:698-702. https://doi.org/10.1001/jama.1994.03510330076038
  14. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45. https://doi.org/10.1016/S0140-6736(95)92348-9
  15. Venkataswamy MM, Goldberg MF, Baena A, Chan J, Jacobs WR Jr, Porcelli SA. In vitro culture medium influences the vaccine efficacy of Mycobacterium bovis BCG. Vaccine 2012;30:1038-49. https://doi.org/10.1016/j.vaccine.2011.12.044
  16. Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess 2013;17:1-372.
  17. The SAGE Working Group on BCG Vaccines and WHO Secretariat. Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections [Internet]. Geneva: World Health Organization; 2017 [cited 2020 May 1]. Available from: https://www.who.int/immunization/sage/meetings/2017/october/1_BCG_report_revised_version_online.pdf.
  18. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998;2:200-7.
  19. Briassoulis G, Karabatsou I, Gogoglou V, Tsorva A. BCG vaccination at three different age groups: response and effectiveness. J Immune Based Ther Vaccines 2005;3:1. https://doi.org/10.1186/1476-8518-3-1
  20. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 2004;291:2086-91. https://doi.org/10.1001/jama.291.17.2086
  21. Sharma AR, Batra G, Kumar M, Mishra A, Singla R, Singh A, et al. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic? Allergol Immunopathol (Madr) 2020;48:507-17. https://doi.org/10.1016/j.aller.2020.05.002
  22. Spencer JC, Ganguly R, Waldman RH. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin. J Infect Dis 1977;136:171-5. https://doi.org/10.1093/infdis/136.2.171
  23. Arts RJ, Moorlag SJ, Novakovic B, Li Y, Wang SY, Oosting M, et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 2018;23:89-100. https://doi.org/10.1016/j.chom.2017.12.010
  24. Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos DA, van Crevel R, et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. J Infect Dis 2015;212:1930-8. https://doi.org/10.1093/infdis/jiv332
  25. WHO timeline - COVID-19 [Internet]. Geneva: World Health Organization; 2020 [cited 2020 May 1]. Available from: https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19.
  26. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 2020;55:105951. https://doi.org/10.1016/j.ijantimicag.2020.105951
  27. Zhao X, Zhang B, Li P, Ma C, Gu J, Hou P, et al. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. Preprint medRxiv at https://doi.org/10.1101/2020.03.17.20037572 (2020).
  28. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
  29. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020;38:1-9.
  30. Clinical management of COVID-19 [Internet]. Geneva: World Health Organization; 2020 [cited 2020 May 1]. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
  31. WHO vaccine-preventable diseases: monitoring system. 2019 global summary [Internet]. Geneva: World Health Organization; 2020 [cited 2020 Apr 20]. Available from: https://apps.who.int/immunization_monitoring/globalsummary/coverages?c=PRT.
  32. People with certain medical conditions [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2020 [cited 2020 May 5]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html#asthma.
  33. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020;323:1775-6.
  34. Rahman M, Sekimoto M, Takamatsu I, Hira K, Shimbo T, Toyoshima K, et al. Economic evaluation of universal BCG vaccination of Japanese infants. Int J Epidemiol 2001;30:380-5. https://doi.org/10.1093/ije/30.2.380
  35. Lahariya C. A brief history of vaccines and vaccination in India. Indian J Med Res 2014;139:491-511.
  36. Sharma A, Kumar Sharma S, Shi Y, Bucci E, Carafoli E, Melino G, et al. BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic? Cell Death Dis 2020;11:516. https://doi.org/10.1038/s41419-020-2720-9
  37. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A 2020;117:17720-6. https://doi.org/10.1073/pnas.2008410117
  38. Rieckmann A, Villumsen M, Sorup S, Haugaard LK, Ravn H, Roth A, et al. Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971-2010. Int J Epidemiol 2017;46:695-705. https://doi.org/10.1093/ije/dyw120
  39. Gruber C, Meinlschmidt G, Bergmann R, Wahn U, Stark K. Is early BCG vaccination associated with less atopic disease? An epidemiological study in German preschool children with different ethnic backgrounds. Pediatr Allergy Immunol 2002;13:177-81. https://doi.org/10.1034/j.1399-3038.2002.01006.x
  40. Kumar J, Meena J. Demystifying BCG vaccine and COVID-19 relationship. Indian Pediatr 2020;57:588-9. https://doi.org/10.1007/s13312-020-1872-0
  41. Ricco M, Gualerzi G, Ranzieri S, Bragazzi NL. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now). Acta Biomed 2020;91:207-13.
  42. ClinicalTrials.gov [Internet]. Bethesda, MD: U.S National Library of Medicine; 2020 [cited 2020 May 5]. Available from: https://clinicaltrials.gov/.

Cited by

  1. Induction of Trained Immunity by Recombinant Vaccines vol.11, 2021, https://doi.org/10.3389/fimmu.2020.611946
  2. COVID-19 Death and BCG Vaccination vol.84, pp.1, 2021, https://doi.org/10.4046/trd.2020.0115
  3. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2 vol.20, pp.9, 2021, https://doi.org/10.1080/14760584.2021.1960161
  4. COVID-19 and Beyond: Exploring Public Health Benefits from Non-Specific Effects of BCG Vaccination vol.9, pp.10, 2021, https://doi.org/10.3390/microorganisms9102120
  5. Reliability of Portable Spirometry Performed in the Korea National Health and Nutrition Examination Survey Compared to Conventional Spirometry vol.84, pp.4, 2021, https://doi.org/10.4046/trd.2021.0016
  6. Citizen science initiative points at childhood BCG vaccination as a risk factor for COVID‐19 vol.68, pp.6, 2021, https://doi.org/10.1111/tbed.14097